JP2013542226A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013542226A5 JP2013542226A5 JP2013536921A JP2013536921A JP2013542226A5 JP 2013542226 A5 JP2013542226 A5 JP 2013542226A5 JP 2013536921 A JP2013536921 A JP 2013536921A JP 2013536921 A JP2013536921 A JP 2013536921A JP 2013542226 A5 JP2013542226 A5 JP 2013542226A5
- Authority
- JP
- Japan
- Prior art keywords
- composition according
- pharmaceutical composition
- group
- antimicrobial agent
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 28
- 208000015181 infectious disease Diseases 0.000 claims description 15
- 230000000813 microbial effect Effects 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 13
- 239000003937 drug carrier Substances 0.000 claims description 12
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 239000004599 antimicrobial Substances 0.000 claims description 9
- 238000004090 dissolution Methods 0.000 claims description 8
- 239000003995 emulsifying agent Substances 0.000 claims description 8
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 7
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- -1 coatings Substances 0.000 claims description 6
- 230000009089 cytolysis Effects 0.000 claims description 6
- 230000002496 gastric effect Effects 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- YZBQHRLRFGPBSL-RXMQYKEDSA-N carbapenem Chemical group C1C=CN2C(=O)C[C@H]21 YZBQHRLRFGPBSL-RXMQYKEDSA-N 0.000 claims description 4
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000000796 flavoring agent Substances 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 229940124307 fluoroquinolone Drugs 0.000 claims description 3
- XUBOMFCQGDBHNK-JTQLQIEISA-N (S)-gatifloxacin Chemical compound FC1=CC(C(C(C(O)=O)=CN2C3CC3)=O)=C2C(OC)=C1N1CCN[C@@H](C)C1 XUBOMFCQGDBHNK-JTQLQIEISA-N 0.000 claims description 2
- OSSNTDFYBPYIEC-UHFFFAOYSA-N 1-ethenylimidazole Chemical compound C=CN1C=CN=C1 OSSNTDFYBPYIEC-UHFFFAOYSA-N 0.000 claims description 2
- OIQOAYVCKAHSEJ-UHFFFAOYSA-N 2-[2,3-bis(2-hydroxyethoxy)propoxy]ethanol;hexadecanoic acid;octadecanoic acid Chemical group OCCOCC(OCCO)COCCO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O OIQOAYVCKAHSEJ-UHFFFAOYSA-N 0.000 claims description 2
- YSLIPUSJNFIFAB-UHFFFAOYSA-N 2-oxopyridine-1-carboxylic acid Chemical class OC(=O)N1C=CC=CC1=O YSLIPUSJNFIFAB-UHFFFAOYSA-N 0.000 claims description 2
- 108010013198 Daptomycin Proteins 0.000 claims description 2
- 108010015899 Glycopeptides Proteins 0.000 claims description 2
- 102000002068 Glycopeptides Human genes 0.000 claims description 2
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 150000001204 N-oxides Chemical class 0.000 claims description 2
- 108010015795 Streptogramin B Proteins 0.000 claims description 2
- 229940126575 aminoglycoside Drugs 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 229960005091 chloramphenicol Drugs 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- 230000006835 compression Effects 0.000 claims description 2
- 238000007906 compression Methods 0.000 claims description 2
- 229920001577 copolymer Polymers 0.000 claims description 2
- 229960002488 dalbavancin Drugs 0.000 claims description 2
- 108700009376 dalbavancin Proteins 0.000 claims description 2
- DOAKLVKFURWEDJ-QCMAZARJSA-N daptomycin Chemical compound C([C@H]1C(=O)O[C@H](C)[C@@H](C(NCC(=O)N[C@@H](CCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C(=O)N1)[C@H](C)CC(O)=O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CCCCCCCCC)C(=O)C1=CC=CC=C1N DOAKLVKFURWEDJ-QCMAZARJSA-N 0.000 claims description 2
- 229960005484 daptomycin Drugs 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000002270 dispersing agent Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 229960003760 florfenicol Drugs 0.000 claims description 2
- 235000013355 food flavoring agent Nutrition 0.000 claims description 2
- 229960003923 gatifloxacin Drugs 0.000 claims description 2
- ZRCVYEYHRGVLOC-HYARGMPZSA-N gemifloxacin Chemical compound C1C(CN)C(=N/OC)/CN1C(C(=C1)F)=NC2=C1C(=O)C(C(O)=O)=CN2C1CC1 ZRCVYEYHRGVLOC-HYARGMPZSA-N 0.000 claims description 2
- 229960003170 gemifloxacin Drugs 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 239000003835 ketolide antibiotic agent Substances 0.000 claims description 2
- 229960003376 levofloxacin Drugs 0.000 claims description 2
- 229960003907 linezolid Drugs 0.000 claims description 2
- TYZROVQLWOKYKF-ZDUSSCGKSA-N linezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C(C=C1F)=CC=C1N1CCOCC1 TYZROVQLWOKYKF-ZDUSSCGKSA-N 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 239000003120 macrolide antibiotic agent Substances 0.000 claims description 2
- 229940041033 macrolides Drugs 0.000 claims description 2
- FABPRXSRWADJSP-MEDUHNTESA-N moxifloxacin Chemical compound COC1=C(N2C[C@H]3NCCC[C@H]3C2)C(F)=CC(C(C(C(O)=O)=C2)=O)=C1N2C1CC1 FABPRXSRWADJSP-MEDUHNTESA-N 0.000 claims description 2
- 229960003702 moxifloxacin Drugs 0.000 claims description 2
- VHFGEBVPHAGQPI-MYYQHNLBSA-N oritavancin Chemical compound O([C@@H]1C2=CC=C(C(=C2)Cl)OC=2C=C3C=C(C=2O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O[C@@H]2O[C@@H](C)[C@H](O)[C@@](C)(NCC=4C=CC(=CC=4)C=4C=CC(Cl)=CC=4)C2)OC2=CC=C(C=C2Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]2C(=O)N[C@@H]1C(N[C@H](C1=CC(O)=CC(O)=C1C=1C(O)=CC=C2C=1)C(O)=O)=O)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@@H](O)[C@H](C)O1 VHFGEBVPHAGQPI-MYYQHNLBSA-N 0.000 claims description 2
- 229960001607 oritavancin Drugs 0.000 claims description 2
- 108010006945 oritavancin Proteins 0.000 claims description 2
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 claims description 2
- 229920000768 polyamine Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000003755 preservative agent Substances 0.000 claims description 2
- YGXCETJZBDTKRY-DZCVGBHJSA-N pristinamycin IA Chemical compound N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YGXCETJZBDTKRY-DZCVGBHJSA-N 0.000 claims description 2
- 150000007660 quinolones Chemical class 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- ONUMZHGUFYIKPM-MXNFEBESSA-N telavancin Chemical compound O1[C@@H](C)[C@@H](O)[C@](NCCNCCCCCCCCCC)(C)C[C@@H]1O[C@H]1[C@H](OC=2C3=CC=4[C@H](C(N[C@H]5C(=O)N[C@H](C(N[C@@H](C6=CC(O)=C(CNCP(O)(O)=O)C(O)=C6C=6C(O)=CC=C5C=6)C(O)=O)=O)[C@H](O)C5=CC=C(C(=C5)Cl)O3)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](NC(=O)[C@@H](CC(C)C)NC)[C@H](O)C3=CC=C(C(=C3)Cl)OC=2C=4)O[C@H](CO)[C@@H](O)[C@@H]1O ONUMZHGUFYIKPM-MXNFEBESSA-N 0.000 claims description 2
- 229960005240 telavancin Drugs 0.000 claims description 2
- 108010089019 telavancin Proteins 0.000 claims description 2
- 229920002554 vinyl polymer Polymers 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000080 wetting agent Substances 0.000 claims description 2
- KGPGQDLTDHGEGT-JCIKCJKQSA-N zeven Chemical compound C=1C([C@@H]2C(=O)N[C@H](C(N[C@H](C3=CC(O)=C4)C(=O)NCCCN(C)C)=O)[C@H](O)C5=CC=C(C(=C5)Cl)OC=5C=C6C=C(C=5O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@H](O5)C(O)=O)NC(=O)CCCCCCCCC(C)C)OC5=CC=C(C=C5)C[C@@H]5C(=O)N[C@H](C(N[C@H]6C(=O)N2)=O)C=2C(Cl)=C(O)C=C(C=2)OC=2C(O)=CC=C(C=2)[C@H](C(N5)=O)NC)=CC=C(O)C=1C3=C4O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O KGPGQDLTDHGEGT-JCIKCJKQSA-N 0.000 claims description 2
- 150000003952 β-lactams Chemical class 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 8
- 102000016736 Cyclin Human genes 0.000 claims 1
- 108050006400 Cyclin Proteins 0.000 claims 1
- 108010034396 Streptogramins Proteins 0.000 claims 1
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims 1
- 238000009506 drug dissolution testing Methods 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 229940041030 streptogramins Drugs 0.000 claims 1
- 125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims 1
- 238000000034 method Methods 0.000 description 8
- 229940041011 carbapenems Drugs 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- IBXDWOGXZNFARB-IBGZPJMESA-N CC(NC[C@@H](CN1c2ccc(-c3ccc(CNCCCF)cc3)c(F)c2)OC1=O)=O Chemical compound CC(NC[C@@H](CN1c2ccc(-c3ccc(CNCCCF)cc3)c(F)c2)OC1=O)=O IBXDWOGXZNFARB-IBGZPJMESA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 244000292604 Salvia columbariae Species 0.000 description 1
- 235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 1
- 235000001498 Salvia hispanica Nutrition 0.000 description 1
- 108010015791 Streptogramin A Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000014167 chia Nutrition 0.000 description 1
- 229940041028 lincosamides Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- DAIKHDNSXMZDCU-FQTGFAPKSA-N pristinamycin IIA Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2 DAIKHDNSXMZDCU-FQTGFAPKSA-N 0.000 description 1
- DAIKHDNSXMZDCU-OUDXUNEISA-N pristinamycin-IIA Natural products CC(C)[C@H]1OC(=O)C2=CCCN2C(=O)c3coc(CC(=O)C[C@H](O)C=C(C)C=CCNC(=O)C=C[C@@H]1C)n3 DAIKHDNSXMZDCU-OUDXUNEISA-N 0.000 description 1
- BTTNOGHPGJANSW-IBGZPJMESA-N radezolid Chemical compound O=C1O[C@@H](CNC(=O)C)CN1C1=CC=C(C=2C=CC(CNCC=3NN=NC=3)=CC=2)C(F)=C1 BTTNOGHPGJANSW-IBGZPJMESA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40883010P | 2010-11-01 | 2010-11-01 | |
| US61/408,830 | 2010-11-01 | ||
| PCT/US2011/058743 WO2012061360A2 (en) | 2010-11-01 | 2011-11-01 | Pharmaceutical compositions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013542226A JP2013542226A (ja) | 2013-11-21 |
| JP2013542226A5 true JP2013542226A5 (https=) | 2014-12-18 |
| JP5902188B2 JP5902188B2 (ja) | 2016-04-13 |
Family
ID=46025057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013536921A Expired - Fee Related JP5902188B2 (ja) | 2010-11-01 | 2011-11-01 | 薬学的組成物 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9409896B2 (https=) |
| EP (1) | EP2635307B1 (https=) |
| JP (1) | JP5902188B2 (https=) |
| KR (1) | KR20140022773A (https=) |
| CN (1) | CN103379917B (https=) |
| AU (1) | AU2011323594C1 (https=) |
| BR (1) | BR112013010714A2 (https=) |
| CA (1) | CA2816077C (https=) |
| EA (1) | EA028054B1 (https=) |
| ES (1) | ES2824898T3 (https=) |
| HU (1) | HUE051133T2 (https=) |
| IL (1) | IL225952A0 (https=) |
| MX (1) | MX359366B (https=) |
| NZ (1) | NZ609964A (https=) |
| PH (1) | PH12013500882A1 (https=) |
| PT (1) | PT2635307T (https=) |
| SG (2) | SG190117A1 (https=) |
| UA (1) | UA114469C2 (https=) |
| WO (1) | WO2012061360A2 (https=) |
| ZA (1) | ZA201303177B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2607526C2 (ru) | 2009-11-23 | 2017-01-10 | Кьюбист Фармасьютикалз ЭлЭлСи | Липопептидные композиции и родственные способы |
| NZ610638A (en) * | 2010-11-24 | 2015-05-29 | Melinta Therapeutics Inc | Pharmaceutical compositions comprising radezolid |
| CN104364240B (zh) * | 2012-06-08 | 2017-02-22 | 四川贝力克生物技术有限责任公司 | 一种用于预防或治疗分支杆菌疾病的药物 |
| ES2866935T3 (es) | 2014-01-10 | 2021-10-20 | Anaptysbio Inc | Anticuerpos dirigidos contra interleucina-33 (IL-33) |
| EP4058020A4 (en) * | 2019-12-26 | 2023-04-12 | Santa Farma Ilaç Sanayi A.S. | SOLID ORAL PHARMACEUTICAL GEMIFLOXACIN MESYLATE COMPOSITION WITH IMPROVED RELEASE PROFILE AND MECHANISM OF DISINTEGRATION |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998007429A2 (en) | 1996-05-24 | 1998-02-26 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| CN1207895A (zh) * | 1997-08-12 | 1999-02-17 | 陕西省西安制药厂 | 一种克拉霉素胶囊 |
| DE69811233T2 (de) | 1997-10-27 | 2003-11-20 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| KR19990080453A (ko) * | 1998-04-17 | 1999-11-05 | 성재갑 | 비가역성 hiv 프로테아제 억제제를 함유하는 약제학적 조성물 |
| US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| US20020119196A1 (en) | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
| WO2003004001A1 (en) | 2001-07-06 | 2003-01-16 | Lifecycle Pharma A/S | Controlled agglomeration |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| EP1656370B1 (en) | 2003-06-03 | 2012-08-15 | Rib-X Pharmaceuticals, Inc. | Biaryl heterocyclic compounds and methods of making and using the same |
| SI1656370T1 (sl) * | 2003-06-03 | 2012-12-31 | Rib-X Pharmaceuticals, Inc. | Biarilne heterociklične spojine in postopki za njihovo izdelavo in uporabo |
| CA2540984C (en) * | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| KR20050104152A (ko) * | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
| EP2974718A1 (en) * | 2005-04-29 | 2016-01-20 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| JP5534497B2 (ja) * | 2005-06-08 | 2014-07-02 | メリンタ セラピューティクス，インコーポレイテッド | トリアゾール類の合成方法 |
| CA2644311C (en) * | 2006-03-01 | 2012-07-10 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| TW200800179A (en) * | 2006-03-06 | 2008-01-01 | Wyeth Corp | Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| AU2007230549A1 (en) * | 2006-03-27 | 2007-10-04 | Panacea Biotec Ltd | Sustained release pharmaceutical composition on the basis of a release system comprising an acid-soluble polymer and a ph-dependent polymer. |
| WO2008085913A1 (en) | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
| US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
| WO2010046933A2 (en) * | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Pharmaceutical compositions of taste-masked linezolid |
-
2011
- 2011-11-01 CN CN201180063510.8A patent/CN103379917B/zh not_active Expired - Fee Related
- 2011-11-01 MX MX2013004711A patent/MX359366B/es active IP Right Grant
- 2011-11-01 JP JP2013536921A patent/JP5902188B2/ja not_active Expired - Fee Related
- 2011-11-01 BR BR112013010714A patent/BR112013010714A2/pt not_active IP Right Cessation
- 2011-11-01 US US13/882,698 patent/US9409896B2/en active Active
- 2011-11-01 PH PH1/2013/500882A patent/PH12013500882A1/en unknown
- 2011-11-01 ES ES11838664T patent/ES2824898T3/es active Active
- 2011-11-01 PT PT118386648T patent/PT2635307T/pt unknown
- 2011-11-01 WO PCT/US2011/058743 patent/WO2012061360A2/en not_active Ceased
- 2011-11-01 EP EP11838664.8A patent/EP2635307B1/en active Active
- 2011-11-01 NZ NZ609964A patent/NZ609964A/en not_active IP Right Cessation
- 2011-11-01 SG SG2013033865A patent/SG190117A1/en unknown
- 2011-11-01 EA EA201390646A patent/EA028054B1/ru not_active IP Right Cessation
- 2011-11-01 UA UAA201306779A patent/UA114469C2/uk unknown
- 2011-11-01 HU HUE11838664A patent/HUE051133T2/hu unknown
- 2011-11-01 SG SG10201508982TA patent/SG10201508982TA/en unknown
- 2011-11-01 KR KR1020137013955A patent/KR20140022773A/ko not_active Abandoned
- 2011-11-01 CA CA2816077A patent/CA2816077C/en active Active
- 2011-11-01 AU AU2011323594A patent/AU2011323594C1/en not_active Ceased
-
2013
- 2013-04-25 IL IL225952A patent/IL225952A0/en unknown
- 2013-04-30 ZA ZA2013/03177A patent/ZA201303177B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3228314B1 (en) | Suloctidil for use to treat microbial infections | |
| JP6297674B2 (ja) | 感染を処置する化合物及び方法 | |
| KR100780983B1 (ko) | 소염제의 분산성 제제 | |
| JP2013542226A5 (https=) | ||
| JP2009514936A5 (https=) | ||
| JP2010527346A5 (https=) | ||
| CN1761487A (zh) | 抗炎剂的可分散制剂 | |
| CN105492005A (zh) | 治疗包括乳房炎的微生物感染的方法 | |
| RU2009121812A (ru) | Производные 5-гидроксиметилоксазолидин-2-она | |
| KR102640532B1 (ko) | 신규한 테비페넴 피복실 속방형 및 변형 방출형 경구 투여형 | |
| JP5674648B2 (ja) | 抗生物質およびコルチコステロイドを含む組成物 | |
| KR102237887B1 (ko) | 항생제를 사용하여 과체중 및 비만 환자에서 감염을 치료하는 방법 | |
| US11382885B2 (en) | Compositions for treating fungal and bacterial biofilms and methods of using the same | |
| AU2011323594B2 (en) | Pharmaceutical compositions | |
| WO2020117755A1 (en) | Compositions and methods for treating biofilms | |
| KR102190173B1 (ko) | Ｎｓａｉｄ 투여 및 관련 조성물, 방법 및 시스템 | |
| KR101944124B1 (ko) | 약학 조성물 | |
| RU2531937C2 (ru) | Состав и способ получения глазной мази | |
| HK1090838A (en) | Dispersible formulation of an anti-inflammatory agent |